Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:

NCT ID: NCT02262741 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Start date: October 15, 2014
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.

NCT ID: NCT02262221 Suspended - Clinical trials for Head and Neck Cancer

Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer

HETeCo
Start date: June 2014
Phase: N/A
Study type: Interventional

Randomized, multicenter trial to evaluate the cost-effectiveness of 2 different follows up programs in head and neck cancer survivors. Patients in complete remission at month 6 (+/- 1 month) after curative treatment will be randomized in two arms according to 2 different follow up approaches: Non Intensive Follow up approach (Arm A) with no radiologic evaltuations scheduled, but required only at the occurence of any signs or symptoms and Intensive Follow up approach (Arm B) with scheduled radiologic evaluations.

NCT ID: NCT02261181 Completed - Clinical trials for Head and Neck Cancer

Preemptive Treatment With XONRID to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients

Start date: January 2015
Phase: N/A
Study type: Interventional

There is a strong need to study products with a preemptive role in radiation dermatitis development, with a trial design taking in account patient subjective evaluation and compliance. XONRID is a promising device for radiation high grade dermatitis prevention; it is a topical gel that prevents and treats skin symptoms such as erythema, itching, burning sensation and pruritus, induced by radiotherapy or other causes.

NCT ID: NCT02255773 Completed - Clinical trials for Head and Neck Cancer

Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures

Start date: November 4, 2014
Phase: N/A
Study type: Interventional

The goal of this research study is to learn more about fatigue and how it affects your behavior as well as your willingness to learn new behaviors.

NCT ID: NCT02254044 Terminated - Clinical trials for Carcinoma, Squamous Cell

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Start date: October 2003
Phase: Phase 1
Study type: Interventional

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

NCT ID: NCT02254018 Completed - Clinical trials for Head and Neck Neoplasms

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Start date: September 1, 2002
Phase: Phase 1
Study type: Interventional

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

NCT ID: NCT02253238 Active, not recruiting - Clinical trials for Head and Neck Cancer

Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients

Start date: January 7, 2014
Phase: N/A
Study type: Interventional

The goal of this research study is to learn if home-use of devices to identify dehydration risk, when added to standard care, will help to lower hospitalizations and emergency room visits (and related costs) in patients with head and neck cancer. CYCORE is a software-based system that enables comprehensive collection, storage and analysis of information related to cancer research and clinical care. In this study, those in the CYCORE group use devices at home to measure their dehydration risk. This information is monitored by their clinicians. Those in the standard care group complete health based surveys, as do those in the CYCORE group.

NCT ID: NCT02252042 Completed - Clinical trials for Head and Neck Squamous Cell Cancer

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Start date: November 17, 2014
Phase: Phase 3
Study type: Interventional

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) versus standard treatment (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC). Participants will be randomly assigned to receive either pembrolizumab or Investigator's choice of standard treatment. The primary study hypothesis is that pembrolizumab treatment prolongs Overall Survival (OS) when compared to standard treatment.

NCT ID: NCT02251730 Completed - Clinical trials for Head and Neck Neoplasms

Smoking Cessation in Head and Neck Cancer Patients Receiving Curative Radiation Therapy

Start date: August 2014
Phase: Phase 2
Study type: Interventional

To propose a feasibility study of introducing a smoking cessation program in head and neck cancer patients with planned radiotherapy. The study will feature the feasibility, safety, and efficacy of a prospective smoking cessation program during head and neck irradiation.

NCT ID: NCT02251639 Withdrawn - Clinical trials for Head and Neck Cancer

Diagnostic Aids for Detection and Diagnosis of Oral Cancer

Start date: October 2014
Phase: Phase 1
Study type: Interventional

The goal of this clinical study is to find out if certain instruments/devices, such as wide field fluorescence imaging point spectroscopy and/or brush cytology, can help health care providers find mouth cancer more quickly than a standard oral clinical exam.